市場調査レポート

商品コード

1791210

ビクタルビ市場レポート：2031年までの動向、予測、競合分析

Biktarvy Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日: 2025年08月14日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日

カスタマイズ可能

適宜更新あり

価格

PDF (Single User License)

USD 3,850 571,725円

レポートPDFを購入者の1名のみがご利用頂けるライセンスです。PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能ですが、編集はできません。PDF内コンテンツは印刷可能ですが、印刷したもののご利用は、PDFのご利用範囲に準拠します。

PDF (2 Users License)

USD 4,650 690,525円

レポートPDFを同じ事業所内の2名までがご利用頂けるライセンスです。PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能ですが、編集はできません。PDF内コンテンツは印刷可能ですが、印刷したもののご利用は、PDFのご利用範囲に準拠します。

PDF (5 Users License)

USD 5,350 794,475円

レポートPDFを同じ事業所内の5名までがご利用頂けるライセンスです。PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能ですが、編集はできません。PDF内コンテンツは印刷可能ですが、印刷したもののご利用は、PDFのご利用範囲に準拠します。

PDF (Corporate License)

USD 7,050 1,046,925円

レポートPDFを企業内すべての方が使用頂けるライセンスです。ご利用人数の制限はありませんが、同一国内にある事業所のみとなり、海外支店などは含まれません。PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能ですが、編集は出来ません。PDF内コンテンツの印刷は可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.50円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のビクタルビ市場の将来は、病院と小売薬局市場における機会があり、有望視されています。世界のビクタルビ市場は、2025～2031年にかけてCAGR 2.7％で成長すると予想されます。この市場の主な促進要因は、HIV/AIDSの有病率の上昇、啓発とスクリーニングプログラムの増加、単剤レジメンへの嗜好の高まりです。

Lucintelの予測では、タイプ別ではジェネリック医薬品が予測期間中に高い成長を遂げる見込みです。
用途別では、小売薬局が高い成長を遂げると予測されます。
地域別では、北米が予測期間中に最も高い成長が見込まれます。

150ページ以上の包括的なレポートで、ビジネスの意思決定に役立つ貴重な洞察を得ることができます。

ビクタルビ市場の新たな動向

ビクタルビ市場は強固ではあるものの、不変ではありません。HIV治療環境全体における今後の方向性や位置づけを形成する、非常に重要な動向がいくつも現れています。これらの動向の中には、長時間作用型注射剤の創出と普及、併存疾患を有する患者の治療重視の高まり、曝露前予防薬（PrEP）の使用拡大、単剤レジメンの継続的関連性、特許切れとジェネリック医薬品の競合による影響の可能性などが含まれます。将来の市場動向を予測するには、こうした動向に関する知識が不可欠です。

長時間作用型注射療法：カボテグラビルやリルピビリン（カベヌーバ）を含む長時間作用型注射抗レトロウイルス療法の開発と使用の増加は、HIV治療における大きな動向です。これらの治療法は、投与回数が少ない（例えば、月1回または隔月1回）という利点をもたらし、錠剤の負担を最小限にすることで患者の服薬アドヒアランスと患者満足度を簡素化することができます。ビクタルビは1日1回の経口投与というシンプルなレジメンであるのに対し、投与頻度がさらに少ないという魅力は一部の患者にとって魅力的であり、長期的にはビクタルビの市場シェアに影響を与える可能性があります。
併存疾患を有する患者の治療重視の高まり：HIV感染者は、心血管疾患、腎機能障害、骨健康障害などの合併症を有することが多くなっています。このため、ウイルス抑制効果が高いだけでなく、これらの併存疾患を考慮した安全で忍容性の高いHIV治療薬が必要とされています。高齢患者や併存疾患を有する患者におけるビクタルビに関する長期データは、現在進行中の研究および臨床試験で研究されており、市場においてこれらの複雑な患者の要件を満たすことの重要性が強調されています。
曝露前予防措置の拡大：ビクタルビ自体はPrEPとして承認されていませんが、HIV予防レジメンへの注目の高まりとPrEP使用の拡大は、HIV市場全体の規模に影響を与えます。PrEPの新規HIV感染予防効果は、ひいては将来の治療市場規模に影響を与える可能性があります。ビクタルビを製造するGileadは、デコイなど他の薬剤でPrEP市場でも存在感を示しており、治療と予防の両方により一般的な戦略的関心があることを示唆しています。新しい長時間作用型PrEPの導入により、状況はさらに変化する可能性があります。
単一錠剤レジメンの継続的優位性：ビクタルビなどの単剤レジメンは、シンプルで服薬アドヒアランスの向上を促すため、ほとんどのHIV感染者にとって標準的な治療法となっています。1日1錠を服用するだけという手軽さは、治療を容易にし、より良好な転帰をもたらします。ビクタルビの成功は、忍容性の高い安全性プロファイルを持つ、小規模だが効果的なSTRという位置づけに由来しています。この動向は、STRが市場において非常に大きなシェアを維持することを意味していますが、今後、長時間作用型の新製品との競合が予想されます。
特許切れとジェネリック医薬品の競合による潜在的影響：ビクタルビは現在特許保護下にありますが、いずれ特許が失効すればジェネリック医薬品との競合が可能になります。抗レトロウイルス薬のジェネリック医薬品は治療費を劇的に削減する可能性があり、ビクタルビなどのブランド薬の市場シェアと収益に影響を与える可能性があります。Gileadは、市場の優位性を維持するために、新しく革新的なHIV治療薬を開発し、このような将来の競争に備える必要があります。

このような新たな動向はすべて、ビクタルビ市場を再構築するために組み合わされています。ビクタルビは現在、単剤レジメンのトップとしての地位を堅持していますが、長時間作用型注射剤の利用可能性が高まり、併存疾患のある患者の治療が重視されるようになっているため、それに対応しなければならないと思われます。PrEPの成長は治療薬全体の市場規模に影響を与える可能性があり、最終的にはジェネリック医薬品の発売によって価格圧力がかかると思われます。Gileadの革新的な能力と治療開発能力は、このような市場力学の変化を乗り切り、HIV治療領域で揺るぎない地位を維持するための鍵となると思われます。

ビクタルビ市場の最近の動向

ビクタルビ市場を取り巻く現在の出来事は、HIV治療の第一選択薬としてのリーダーシップを確認することに集中しています。これらの出来事には、長期的な有効性と安全性データの導入、共同感染者などさまざまな患者集団への適用に関する研究、患者の利便性と治療成績を改善するための新しい製剤の評価などが含まれます。これらはすべて、ビクタルビの使用を拡大し、新たなHIV治療の展望の中でその地位を確認することを目的としています。

長期有効性と安全性データ：現在進行中の臨床試験と実臨床試験により、ビクタルビの有効性と安全性に関する長期データが得られています。CROI（Conference on Retroviruses and Opportunistic Infections：レトロウイルスと日和見感染症に関する学会）を含む主要な学会での発表では、通常、ビクタルビを投与された患者における持続的なウイルス抑制と良好な安全性プロファイルを示す複数年の結果が示されています。このことは、ビクタルビが長期的に安定した治療選択肢であることを裏付けています。
特定の患者集団における研究：HIV感染者の特定のサブグループにおけるビクタルビの有効性と安全性を評価するための研究が実施されています。これには、治療未経験者、他の抗レトロウイルスレジメンからの切り替え患者、高齢者、B型肝炎ウイルス（HBV）重複感染などの併存疾患を有する患者を対象とした研究が含まれます。これらの研究から得られた知見は、治療の指針となり、より多くの患者群にビクタルビの価値に関する知識を広めるのに役立ちます。例えば、ビクタルビに切り替えたHIV/HBV重複感染患者において、高いウイルス抑制率が実証されています。
新しい製剤と投与方法の検討：ビクタルビは現在、1日1回投与の経口錠剤として販売されていますが、HIV治療分野全体では、長時間作用型の製剤に関する研究が活発に行われています。短期的にはビクタルビに特化したものではありませんが、ドラッグデリバリーシステムの技術進歩により、利便性とアドヒアランスのさらなる向上を目的とした、ビクタルビまたはその各成分の再製剤が将来的に開発される可能性があります。
他の抗レトロウイルスレジメンと比較した相対的な有効性と安全性の研究：治療におけるビクタルビの位置づけをさらに明確にするため、臨床試験を通じて、広く使用されている他の抗レトロウイルス療法レジメンと比較されています。このような臨床試験では、有効性、安全性、忍容性が評価され、臨床医が十分な情報を得た上で治療を決定するのに役立っています。このような相対的な有効性と安全性の研究から得られた良好な結果は、ビクタルビを第一選択薬として推奨するものです。
現実のエビデンスの収集対照臨床試験以外では、実臨床におけるエビデンスの収集と分析がより重要になってきています。これらの試験は、臨床試験の稀なプロトコール条件以外の異種患者群におけるビクタルビの有効性と忍容性を明らかにすることで、実臨床の条件下でビクタルビがどのように作用するかを評価するものです。実臨床におけるエビデンスは、臨床試験情報を補足し、治療推奨にさらに貢献するために使用することができます。

これらの最近の進歩は、HIV管理におけるビクタルビの利用を最大化するための継続的な努力を強調するものです。長期データの蓄積、特殊な集団における研究、HIV治療研究の一般的動向はすべて、HIVとともに生きる個人の生活を向上させる上でのビクタルビの位置づけと有望性をよりよく理解することにつながっています。これらの進歩は、ビクタルビが現代のHIV治療時代において不可欠な存在であることをさらに証明するものです。

List of Figures

Figure 1.1: Trends and Forecast for the Global Biktarvy Market
Figure 2.1: Usage of Biktarvy Market
Figure 2.2: Classification of the Global Biktarvy Market
Figure 2.3: Supply Chain of the Global Biktarvy Market
Figure 2.4: Driver and Challenges of the Biktarvy Market
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 4.1: Global Biktarvy Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Biktarvy Market ($B) by Type
Figure 4.3: Forecast for the Global Biktarvy Market ($B) by Type
Figure 4.4: Trends and Forecast for Brand Drugs in the Global Biktarvy Market (2019-2031)
Figure 4.5: Trends and Forecast for Generic Drugs in the Global Biktarvy Market (2019-2031)
Figure 5.1: Global Biktarvy Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Biktarvy Market ($B) by Application
Figure 5.3: Forecast for the Global Biktarvy Market ($B) by Application
Figure 5.4: Trends and Forecast for Hospitals in the Global Biktarvy Market (2019-2031)
Figure 5.5: Trends and Forecast for Retail Pharmacy in the Global Biktarvy Market (2019-2031)
Figure 5.6: Trends and Forecast for Others in the Global Biktarvy Market (2019-2031)
Figure 6.1: Trends of the Global Biktarvy Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Biktarvy Market ($B) by Region (2025-2031)
Figure 7.1: Trends and Forecast for the North American Biktarvy Market (2019-2031)
Figure 7.2: North American Biktarvy Market by Type in 2019, 2024, and 2031
Figure 7.3: Trends of the North American Biktarvy Market ($B) by Type (2019-2024)
Figure 7.4: Forecast for the North American Biktarvy Market ($B) by Type (2025-2031)
Figure 7.5: North American Biktarvy Market by Application in 2019, 2024, and 2031
Figure 7.6: Trends of the North American Biktarvy Market ($B) by Application (2019-2024)
Figure 7.7: Forecast for the North American Biktarvy Market ($B) by Application (2025-2031)
Figure 7.8: Trends and Forecast for the United States Biktarvy Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Mexican Biktarvy Market ($B) (2019-2031)
Figure 7.10: Trends and Forecast for the Canadian Biktarvy Market ($B) (2019-2031)
Figure 8.1: Trends and Forecast for the European Biktarvy Market (2019-2031)
Figure 8.2: European Biktarvy Market by Type in 2019, 2024, and 2031
Figure 8.3: Trends of the European Biktarvy Market ($B) by Type (2019-2024)
Figure 8.4: Forecast for the European Biktarvy Market ($B) by Type (2025-2031)
Figure 8.5: European Biktarvy Market by Application in 2019, 2024, and 2031
Figure 8.6: Trends of the European Biktarvy Market ($B) by Application (2019-2024)
Figure 8.7: Forecast for the European Biktarvy Market ($B) by Application (2025-2031)
Figure 8.8: Trends and Forecast for the German Biktarvy Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the French Biktarvy Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Spanish Biktarvy Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the Italian Biktarvy Market ($B) (2019-2031)
Figure 8.12: Trends and Forecast for the United Kingdom Biktarvy Market ($B) (2019-2031)
Figure 9.1: Trends and Forecast for the APAC Biktarvy Market (2019-2031)
Figure 9.2: APAC Biktarvy Market by Type in 2019, 2024, and 2031
Figure 9.3: Trends of the APAC Biktarvy Market ($B) by Type (2019-2024)
Figure 9.4: Forecast for the APAC Biktarvy Market ($B) by Type (2025-2031)
Figure 9.5: APAC Biktarvy Market by Application in 2019, 2024, and 2031
Figure 9.6: Trends of the APAC Biktarvy Market ($B) by Application (2019-2024)
Figure 9.7: Forecast for the APAC Biktarvy Market ($B) by Application (2025-2031)
Figure 9.8: Trends and Forecast for the Japanese Biktarvy Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Indian Biktarvy Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the Chinese Biktarvy Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the South Korean Biktarvy Market ($B) (2019-2031)
Figure 9.12: Trends and Forecast for the Indonesian Biktarvy Market ($B) (2019-2031)
Figure 10.1: Trends and Forecast for the ROW Biktarvy Market (2019-2031)
Figure 10.2: ROW Biktarvy Market by Type in 2019, 2024, and 2031
Figure 10.3: Trends of the ROW Biktarvy Market ($B) by Type (2019-2024)
Figure 10.4: Forecast for the ROW Biktarvy Market ($B) by Type (2025-2031)
Figure 10.5: ROW Biktarvy Market by Application in 2019, 2024, and 2031
Figure 10.6: Trends of the ROW Biktarvy Market ($B) by Application (2019-2024)
Figure 10.7: Forecast for the ROW Biktarvy Market ($B) by Application (2025-2031)
Figure 10.8: Trends and Forecast for the Middle Eastern Biktarvy Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the South American Biktarvy Market ($B) (2019-2031)
Figure 10.10: Trends and Forecast for the African Biktarvy Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Biktarvy Market
Figure 11.2: Market Share (%) of Top Players in the Global Biktarvy Market (2024)
Figure 12.1: Growth Opportunities for the Global Biktarvy Market by Type
Figure 12.2: Growth Opportunities for the Global Biktarvy Market by Application
Figure 12.3: Growth Opportunities for the Global Biktarvy Market by Region
Figure 12.4: Emerging Trends in the Global Biktarvy Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Biktarvy Market by Type and Application
Table 1.2: Attractiveness Analysis for the Biktarvy Market by Region
Table 1.3: Global Biktarvy Market Parameters and Attributes
Table 3.1: Trends of the Global Biktarvy Market (2019-2024)
Table 3.2: Forecast for the Global Biktarvy Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Biktarvy Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Biktarvy Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Biktarvy Market (2025-2031)
Table 4.4: Trends of Brand Drugs in the Global Biktarvy Market (2019-2024)
Table 4.5: Forecast for Brand Drugs in the Global Biktarvy Market (2025-2031)
Table 4.6: Trends of Generic Drugs in the Global Biktarvy Market (2019-2024)
Table 4.7: Forecast for Generic Drugs in the Global Biktarvy Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Biktarvy Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Biktarvy Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Biktarvy Market (2025-2031)
Table 5.4: Trends of Hospitals in the Global Biktarvy Market (2019-2024)
Table 5.5: Forecast for Hospitals in the Global Biktarvy Market (2025-2031)
Table 5.6: Trends of Retail Pharmacy in the Global Biktarvy Market (2019-2024)
Table 5.7: Forecast for Retail Pharmacy in the Global Biktarvy Market (2025-2031)
Table 5.8: Trends of Others in the Global Biktarvy Market (2019-2024)
Table 5.9: Forecast for Others in the Global Biktarvy Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2025-2031)
Table 7.1: Trends of the North American Biktarvy Market (2019-2024)
Table 7.2: Forecast for the North American Biktarvy Market (2025-2031)
Table 7.3: Market Size and CAGR of Various Type in the North American Biktarvy Market (2019-2024)
Table 7.4: Market Size and CAGR of Various Type in the North American Biktarvy Market (2025-2031)
Table 7.5: Market Size and CAGR of Various Application in the North American Biktarvy Market (2019-2024)
Table 7.6: Market Size and CAGR of Various Application in the North American Biktarvy Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Biktarvy Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Biktarvy Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Biktarvy Market (2019-2031)
Table 8.1: Trends of the European Biktarvy Market (2019-2024)
Table 8.2: Forecast for the European Biktarvy Market (2025-2031)
Table 8.3: Market Size and CAGR of Various Type in the European Biktarvy Market (2019-2024)
Table 8.4: Market Size and CAGR of Various Type in the European Biktarvy Market (2025-2031)
Table 8.5: Market Size and CAGR of Various Application in the European Biktarvy Market (2019-2024)
Table 8.6: Market Size and CAGR of Various Application in the European Biktarvy Market (2025-2031)
Table 8.7: Trends and Forecast for the German Biktarvy Market (2019-2031)
Table 8.8: Trends and Forecast for the French Biktarvy Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Biktarvy Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Biktarvy Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Biktarvy Market (2019-2031)
Table 9.1: Trends of the APAC Biktarvy Market (2019-2024)
Table 9.2: Forecast for the APAC Biktarvy Market (2025-2031)
Table 9.3: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2019-2024)
Table 9.4: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2025-2031)
Table 9.5: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2019-2024)
Table 9.6: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Biktarvy Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Biktarvy Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Biktarvy Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Biktarvy Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Biktarvy Market (2019-2031)
Table 10.1: Trends of the ROW Biktarvy Market (2019-2024)
Table 10.2: Forecast for the ROW Biktarvy Market (2025-2031)
Table 10.3: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2019-2024)
Table 10.4: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2025-2031)
Table 10.5: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2019-2024)
Table 10.6: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Biktarvy Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Biktarvy Market (2019-2031)
Table 10.9: Trends and Forecast for the African Biktarvy Market (2019-2031)
Table 11.1: Product Mapping of Biktarvy Suppliers Based on Segments
Table 11.2: Operational Integration of Biktarvy Manufacturers
Table 11.3: Rankings of Suppliers Based on Biktarvy Revenue
Table 12.1: New Product Launches by Major Biktarvy Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Biktarvy Market

The future of the global Biktarvy market looks promising with opportunities in the hospital and retail pharmacy markets. The global Biktarvy market is expected to grow with a CAGR of 2.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of HIV/AIDS, the growing awareness & screening programs, and the increasing preference for single-tablet regimens.

Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
Within the application category, retail pharmacy is expected to witness higher growth.
In terms of region, North America is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Biktarvy Market

The Biktarvy market, as strong as it is, is not fixed. A number of very important trends are emerging that will shape its future direction and position within the overall HIV treatment environment. Some of these trends involve the creation and uptake of long-acting injectable treatments, the growing emphasis on the treatment of patients with comorbidities, the growing use of pre-exposure prophylaxis (PrEP), the continued relevance of single-tablet regimens, and the possible influence of patent losses and generic competition. Knowledge of these trends is essential to forecast future market trends.

Long-Acting Injectable Therapies: Development and increasing use of long-acting injectable antiretroviral therapies, including cabotegravir and rilpivirine (Cabenuva), are a major trend in HIV therapy. These treatments bring the benefit of less frequent dosing (e.g., monthly or bi-monthly), which can simplify patient adherence and patient satisfaction by minimizing the pill burden. Whereas Biktarvy is a simple once-daily oral regimen, the attractiveness of even less-frequent dosing will appeal to some patients and could affect Biktarvy's market share over the long term.
Increased Emphasis on Treating Patients with Comorbidities: Individuals with HIV are increasingly having comorbidities like cardiovascular disease, renal impairment, and bone health disorders. This requires HIV therapies that are not only efficacious in viral suppression but also safe and well-tolerated in the context of these other comorbidities. Long-term data on Biktarvy among older patients and those with comorbidities are being studied in ongoing research and clinical trials, which underscores the relevance of meeting these complicated patient requirements in the market.
Pre-Exposure Prophylaxis Expansion: Although Biktarvy itself is not approved for PrEP, the increasing focus on HIV prevention regimens and the growth in PrEP use impact the size of the overall HIV market. The effectiveness of PrEP in preventing new HIV infections can, in turn, affect the size of the treatment market in the future. Gilead, the company that makes Biktarvy, also has a presence in the market for PrEP with other medications such as Decoy, suggesting a more general strategic interest in both treatment and prevention. The introduction of new, long-acting PrEP forms may further shift the scene.
Ongoing Supremacy of Single-Tablet Regimens: Single-tablet regimens such as Biktarvy have become the standard of care for most individuals with HIV because they are simple and encourage improved adherence. The ease of taking only a single pill a day makes the treatment easier and can result in better outcomes. Biktarvy's success derives in part from its position as a small but effective STR that has a well-tolerated safety profile. This trend lines up with that STRs will maintain a very large share of the market though they will get competition from some new long-acting products on the horizon.
Potential Effect of Patent Expirations and Generic Competition: Although Biktarvy is now under patent protection, the eventual lapse of these patents will allow generic competition. Generic forms of antiretroviral drugs can dramatically reduce the cost of treatment, potentially affecting the market share and revenue of branded medications such as Biktarvy. Gilead must be planning for this future competition by creating new and innovative HIV treatments in order to preserve its market dominance.

These new trends are all combined to reshape the Biktarvy market. Although Biktarvy's current status as a top single-tablet regimen is robust, it will have to adjust to the growing availability of long-acting injectables and the expanding emphasis on treating patients with comorbidities. The growth of PrEP may impact the total treatment market size, and the eventual launch of generics will bring pricing pressures. Gilead's innovative capacity and therapeutic development capabilities will be key in navigating these shifting market dynamics and keeping a solid footing in the HIV treatment space.

Recent Developments in the Biktarvy Market

Current events surrounding the Biktarvy market are focused on affirming its leadership as a first-line HIV treatment. These events include the introduction of long-term efficacy and safety data, studies of its application in varied patient populations such as those with co-infections, and evaluation of new formulations to improve patient convenience and outcomes. All these are aimed at expanding Biktarvy's use and affirming its place in the emerging HIV treatment landscape.

Long-Term Efficacy and Safety Data: Ongoing clinical trials and real-world studies continue to generate long-term data on the efficacy and safety of Biktarvy. Presentations at key conferences, including the Conference on Retroviruses and Opportunistic Infections (CROI), typically include multi-year outcomes showing durable viral suppression and a good safety profile in patients receiving Biktarvy. This supports confidence in Biktarvy as a stable long-term treatment option.
Studies in Specific Patient Populations: Research is being conducted to evaluate the effectiveness and safety of Biktarvy in specific subgroups of people living with HIV. This includes studies in treatment-naive individuals, those switching from other antiretroviral regimens, older adults, and individuals with comorbidities such as hepatitis B virus (HBV) co-infection. Findings from these studies assist in guiding treatment and broadening the knowledge of Biktarvy's value to a wider group of patients. For instance, high viral suppression rates have been demonstrated in patients with HIV/HBV co-infection switching to Biktarvy.
Investigation of New Formulations and Delivery Options: Although Biktarvy is presently marketed as a once-daily oral tablet, there is active research across the overall HIV therapy space for long-acting formulations. Although nonspecific to Biktarvy in the short run, technology advances in drug delivery systems could in the future create reformulated versions of Biktarvy or its individual elements with the goal of further enhancing convenience and adherence.
Relative Efficacy and Safety Studies Compared to Other Antiretroviral Regimens: Further to define its position in therapy, Biktarvy has been compared to other widely used regimens of antiretroviral therapy through clinical trials. Relative efficacy, safety, and tolerability are all evaluated in such studies, which serve to help clinicians make informed treatment decisions. Favorable results from these relative efficacy and safety studies endorse Biktarvy as a preferred first-line treatment.
Collection of Real-World Evidence: Outside of controlled clinical trials, collection and analysis of real-world evidence are becoming more critical. These trials assess how Biktarvy works under real-world clinical practice conditions, revealing its efficacy and tolerability in a heterogeneous group of patients outside the rare protocol conditions of clinical trials. Real-world evidence can be used to supplement clinical trial information and contribute further to treatment recommendations.

These recent advances collectively emphasize the continued efforts to maximize the utilization of Biktarvy in HIV management. The accumulation of long-term data, research in special populations, and the general trends in HIV treatment research are all leading to a better understanding of Biktarvy's place and promise in enhancing the lives of individuals living with HIV. These advances serve to further establish Biktarvy as an integral part of the contemporary HIV treatment era.

Strategic Growth Opportunities in the Biktarvy Market

Strategic growth areas for Biktarvy are to build on its proven efficacy and safety profile to expand its use across various stages of HIV treatment. These areas are to consolidate its role in first-line treatment, emerge as the first choice among those switching treatment regimens, increase its use in patients with co-infections, and look into new formulations to make it more convenient for patients and improve adherence. Building on these areas can further enhance Biktarvy's market presence.

Initial Therapy for Naive Patients: Biktarvy has already made a significant name for itself as an initial therapy for newly diagnosed HIV individuals. Its ability to provide fast and sustained viral suppression, combined with its tolerability profile and single-tablet once-daily regimen, makes it an appealing choice for initial therapy. Ongoing efforts towards educating healthcare professionals and newly diagnosed patients about these advantages can further establish its place in this critical use.
Switch Therapy for Virologically Suppressed Patients: For patients who are already virologically suppressed on alternative antiretroviral regimens but perhaps having issues with tolerability, drug interactions, or pill burden, Biktarvy represents a streamlined and frequently better-tolerated option. Emphasizing Biktarvy as an exemplary switching option through clinical evidence illustrating superior outcomes or patient satisfaction can increase growth in this category.
HIV/HBV Co-infected Individuals Treatment: HIV patients usually present with co-infections, and one such common co-infection is hepatitis B. Biktarvy's efficacy in suppressing both HIV and HBV has been shown in studies, which makes it an important choice for this particular patient group. Increased research and education among healthcare providers who treat co-infected patients can increase Biktarvy's application in this important use.
Long-Acting Formulations Development: Although Biktarvy is already an oral tablet, the direction of long-acting injectable HIV treatments represents a future growth possibility. Gilead's knowledge in developing HIV drugs could be used to develop long-acting versions of Biktarvy or its active ingredients, providing improved convenience and adherence for those who want to take less medication more infrequently.
Pediatric and Adolescent Use: Another opportunity for growth is extending the approved indication of Biktarvy to younger age groups, such as pediatric and adolescent patients. Clinical trials assessing the safety and efficacy of Biktarvy in these patient groups, with subsequent regulatory approvals, can extend its use and offer effective treatment to children and adolescents with HIV.

These strategic growth prospects, from establishing its place in first-line treatment to investigating new forms and broadening its application in certain patient populations, have the potential to greatly affect the Biktarvy market. By targeting these, Gilead is able to further build on the asset strengths of Biktarvy to meet the changing needs of individuals living with HIV while solidifying its leadership in the antiretroviral category.

Biktarvy Market Driver and Challenges

The trajectory of the Biktarvy market is defined by an intersection of drivers and challenges that result from technological advances in HIV therapy, economic determinants affecting drug pricing and availability, and the changing regulatory environment that defines pharmaceutical approvals and guidelines. These dynamics are essential for stakeholders to effectively navigate the market and for individuals living with HIV to obtain best-in-class care.

The factors responsible for driving the Biktarvy market include:

1. High Efficacy and Tolerability: Biktarvy's proven high viral suppression rates and good safety profile are key drivers of its commercial success. Clinical trial and real-world evidence all demonstrate its ability to suppress HIV with fewer side effects, and so it is a first choice for both treatment-naive patients and treatment-experienced patients. Its robust clinical profile favors its prescription by clinicians.

2. Convenient Once-Daily Single-Tablet Regimen: The ease of once-daily single-tablet therapy greatly enhances treatment adherence. For those with a chronic illness such as HIV, pill burden reduction makes their daily life easier and more likely to maintain regular medication, resulting in improved virologic response. This ease is one of the key reasons Biktarvy is so well received.

3. Strong Recommendation in Treatment Guidelines: Most HIV treatment guidelines globally recommend INSTI-based regimens, such as Biktarvy, as the first-line therapy of choice. These recommendations, supported by strong clinical evidence, lead to the use of Biktarvy by healthcare providers as a safe and effective first-line treatment for the majority of individuals with HIV.

4. Ongoing Innovation in HIV Treatment: Ongoing research and development in the HIV sector lend support to success stories of medications such as Biktarvy. Ongoing developments in antiretroviral drugs, aiming for increased efficacy, lower toxicity, and easier convenience, push the market toward newer and superior treatment alternatives. Biktarvy is one such development, aided by the advances in INSTI development.

5. Increased Awareness and Access to HIV Treatment: Global efforts to increase awareness of HIV, increase testing, and enhance access to treatment drive the expansion of the overall HIV drug market, including Biktarvy. As more individuals become diagnosed and connected to care, demand for effective antiretroviral therapies such as Biktarvy continues to increase.

Challenges in the Biktarvy market are:

1. Competition from Other Antiretroviral Therapies: The market for HIV treatment is competitive, with a number of other effective antiretroviral regimens, including other single-tablet regimens and new long-acting injectable therapies. This competition can restrict Biktarvy's market share and impose pricing pressures as manufacturers compete for patient preference and payer coverage.

2. Pricing and Reimbursement Concerns: The affordability of newer antiretroviral agents such as Biktarvy may be problematic, especially where there are constraints in resources or limited insurance cover. Favorable pricing and proper reimbursement policies that are strong must be negotiated so that market access is sustained and widespread use of Biktarvy is enabled.

3. Risk for Long-Term Side Effects and Resistance: Though Biktarvy has a benign safety profile, the risk of long-term side effects, including some that will not be easily recognized, cannot be eliminated. Moreover, despite the high resistance barrier of Biktarvy, drug resistance, which can evolve over time, is a possibility with any antiretroviral regimen, possibly curtailing its long-term efficacy in certain patients.

The Biktarvy market is fueled by its high efficacy, tolerability, convenient presentation, and favorable positioning in treatment guidelines, within a backdrop of continuous innovation and expanding access to HIV care. But it has challenges posed by competition, price and reimbursement complexities, and long-term side effects or resistance risks. Managing these drivers and challenges will be essential for Biktarvy in order to preserve its market leadership and remain an essential part of HIV treatment.

List of Biktarvy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, Biktarvy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Biktarvy companies profiled in this report include:
Gilead Sciences
ABACUS MEDICINE
Hetero Drugs
Gador
BMODESTO

Biktarvy Market by Segment

The study includes a forecast for the global Biktarvy market by type, application, and region.

Biktarvy Market by Type [Value from 2019 to 2031]:

Brand Drugs
Generic Drugs

Biktarvy Market by Application [Value from 2019 to 2031]:

Hospitals
Retail Pharmacy
Others

Biktarvy Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Biktarvy Market

The Biktarvy market, a major HIV treatment segment worldwide, keeps growing in major geographies. Trends are influenced by drivers like growing adoption rates, competition from established and emerging antiretroviral therapies, pricing trends, and regulatory regimes. Gilead Sciences' Biktarvy, a once-daily, single-tablet regimen, has become a popular treatment because of its efficacy, safety profile, and convenience. Yet, market conditions differ significantly between countries, shaped by local healthcare systems, economic conditions, and HIV prevalence. It is important for stakeholders in the pharmaceutical sector and people living with HIV to understand these regional differences.

United States: Biktarvy enjoys robust market leadership in the US, fueled by strong demand and favorable reimbursement. Sales continue to increase, with a 7% year-on-year increase seen in the first quarter of 2025, contributing largely to Gilead's overall revenues. Although long-acting injectables such as Cabenuva represent competitive pressure, Biktarvy's established track record of efficacy and the convenience of a once-daily oral regimen guarantee its continued solid standing. Recent price revisions have taken place, demonstrating a balance between revenue generation and market access for Gilead.
China: Data on recent developments specifically for Biktarvy in China are sparse in the available search results. The overall Chinese pharmaceutical market, though, is seeing growth in traditional and specialty pharmaceuticals. Single-tablet regimens are becoming the norm for HIV, with branded therapies such as Biktarvy gaining strong share in the HIV segment. The overall pharmaceutical trend suggests a growing market for innovative treatments, which could positively impact Biktarvy's future trajectory in the region.
Germany: There are no specific recent developments on Biktarvy in Germany set out in the search results given. Nevertheless, Germany is a major market across Europe, and trends in other large European markets, including attention to single-tablet regimens and the effect of pricing and reimbursement policy, are likely applicable. The general European market will experience competitive prices as a result of policy action, which might influence the market dynamics of Biktarvy in Germany.
India: The search results do not yield particular recent updates on Biktarvy in India. The Indian pharma industry is, however, interested in bolstering its infrastructure to be a world leader. The overall antiviral drug market is growing, led by the rise in viral disease prevalence. As much as Biktarvy is an important global product, its particular market trends in India would be determined by local prices, access initiatives, and the availability of generic antiretrovirals.
Japan: Recent data suggest that Biktarvy is approved and on the market in Japan. This evidence has been presented at international meetings by Gilead, highlighting the safety and efficacy of Biktarvy across a range of patient subgroups. Japan, as with other developed countries, would prefer effective, convenient HIV treatment, which would play in the favor of Biktarvy. Market conditions would be shaped by the healthcare system and regulation in Japan.

Features of the Global Biktarvy Market

Market Size Estimates: Biktarvy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Biktarvy market size by type, application, and region in terms of value ($B).
Regional Analysis: Biktarvy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the Biktarvy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Biktarvy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the Biktarvy market by type (brand drugs and generic drugs), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Biktarvy Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Brand Drugs: Trends and Forecast (2019-2031)
4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Biktarvy Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospitals: Trends and Forecast (2019-2031)
5.4 Retail Pharmacy: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Biktarvy Market by Region

7. North American Biktarvy Market

7.1 Overview
7.2 North American Biktarvy Market by Type
7.3 North American Biktarvy Market by Application
7.4 United States Biktarvy Market
7.5 Mexican Biktarvy Market
7.6 Canadian Biktarvy Market

8. European Biktarvy Market

8.1 Overview
8.2 European Biktarvy Market by Type
8.3 European Biktarvy Market by Application
8.4 German Biktarvy Market
8.5 French Biktarvy Market
8.6 Spanish Biktarvy Market
8.7 Italian Biktarvy Market
8.8 United Kingdom Biktarvy Market

9. APAC Biktarvy Market

9.1 Overview
9.2 APAC Biktarvy Market by Type
9.3 APAC Biktarvy Market by Application
9.4 Japanese Biktarvy Market
9.5 Indian Biktarvy Market
9.6 Chinese Biktarvy Market
9.7 South Korean Biktarvy Market
9.8 Indonesian Biktarvy Market

10. ROW Biktarvy Market

10.1 Overview
10.2 ROW Biktarvy Market by Type
10.3 ROW Biktarvy Market by Application
10.4 Middle Eastern Biktarvy Market
10.5 South American Biktarvy Market
10.6 African Biktarvy Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Biktarvy Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Gilead Sciences
- Company Overview
- Biktarvy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 ABACUS MEDICINE
- Company Overview
- Biktarvy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Hetero Drugs
- Company Overview
- Biktarvy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Gador
- Company Overview
- Biktarvy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 BMODESTO
- Company Overview
- Biktarvy Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

ビクタルビ市場レポート：2031年までの動向、予測、競合分析

Biktarvy Market Report: Trends, Forecast and Competitive Analysis to 2031

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章市場動向と予測分析

第4章世界のビクタルビ市場：タイプ別

第5章世界のビクタルビ市場：用途別

第6章地域分析

第7章北米のビクタルビ市場

第8章欧州のビクタルビ市場

第9章アジア太平洋のビクタルビ市場

第10章その他地域のビクタルビ市場

第11章競合分析

第12章機会と戦略分析

第13章バリューチェーンにおける主要企業の企業プロファイル

第14章付録

List of Figures

List of Tables

Biktarvy Market by Type [Value from 2019 to 2031]:

Biktarvy Market by Application [Value from 2019 to 2031]:

Biktarvy Market by Region [Value from 2019 to 2031]:

This report answers the following 11 key questions:

Table of Contents

1. Executive Summary

2. Market Overview

3. Market Trends & Forecast Analysis

4. Global Biktarvy Market by Type

5. Global Biktarvy Market by Application

6. Regional Analysis

7. North American Biktarvy Market

8. European Biktarvy Market

9. APAC Biktarvy Market

10. ROW Biktarvy Market

11. Competitor Analysis

12. Opportunities & Strategic Analysis

13. Company Profiles of the Leading Players Across the Value Chain

14. Appendix

ビクタルビ市場レポート：2031年までの動向、予測、競合分析

Biktarvy Market Report: Trends, Forecast and Competitive Analysis to 2031

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 市場動向と予測分析

第4章 世界のビクタルビ市場：タイプ別

第5章 世界のビクタルビ市場：用途別

第6章 地域分析

第7章 北米のビクタルビ市場

第8章 欧州のビクタルビ市場

第9章 アジア太平洋のビクタルビ市場

第10章 その他地域のビクタルビ市場

第11章 競合分析

第12章 機会と戦略分析

第13章 バリューチェーンにおける主要企業の企業プロファイル

第14章 付録

List of Figures

List of Tables

Biktarvy Market by Type [Value from 2019 to 2031]:

Biktarvy Market by Application [Value from 2019 to 2031]:

Biktarvy Market by Region [Value from 2019 to 2031]:

This report answers the following 11 key questions:

Table of Contents

1. Executive Summary

2. Market Overview

3. Market Trends & Forecast Analysis

4. Global Biktarvy Market by Type

5. Global Biktarvy Market by Application

6. Regional Analysis

7. North American Biktarvy Market

8. European Biktarvy Market

9. APAC Biktarvy Market

10. ROW Biktarvy Market

11. Competitor Analysis

12. Opportunities & Strategic Analysis

13. Company Profiles of the Leading Players Across the Value Chain

14. Appendix

第1章エグゼクティブサマリー

第2章市場概要

第3章市場動向と予測分析

第4章世界のビクタルビ市場：タイプ別

第5章世界のビクタルビ市場：用途別

第6章地域分析

第7章北米のビクタルビ市場

第8章欧州のビクタルビ市場

第9章アジア太平洋のビクタルビ市場

第10章その他地域のビクタルビ市場

第11章競合分析

第12章機会と戦略分析

第13章バリューチェーンにおける主要企業の企業プロファイル

第14章付録